Breaking News

Financial Report: Pfizer

January 29, 2013

Revenues down 7% in the quarter


4Q Revenues: $15.1 billion (-7%)

4Q Earnings: $6.3 billion (earnings were $1.4 billion in 4Q11)

YTD Revenues: $59.0 billion (-10%)

YTD Earnings: $14.6 billion (+46%)

Comments: U.S. revenues were $5.8 billion in the quarter, down 9% primarily due to the loss of exclusivity of Lipitor (-79% to $584 million) in November 2011 and Geodon in March 2012. International revenues were $9.3 billion, down 5% due to the losses for Lipitor in Europe in 2Q12 and the unfavorable impact of foreign exchange. Lyrica sales in the quarter were up 13% to $1.1 billion. Prevnar/Prevenar sales were up 19% to $993 million. Celebrex sales were up 12% to $750 million. Viagra sales were up 6% to $553 million. Zyvox sales were up 10% to $349 million. Enbrel sales were up 3% to $957 million. Primary care revenues were down 29% to $3.8 billion. Specialty Care revenues were down 4% to $3.7 billion. Established product sales were up 3% to $2.4 billion. Animal health sales were up 6% to $1.2 billion. Consumer Healthcare sales were up 16% to $936 million. Earnings in the quarter were favorably impacted by the sale of the Nutrition business.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks